Pfizer launches OTC Nexium; Celgene appears to gain in patent hearing; Adcock plots major restructuring;

@FiercePharma: Top-read Tues: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing. Story | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Story | Follow @TracyStaton

@EricPFierce: ICYMI: Takeda now 5 for 6 in defending Actos cases at trial. Article | Follow @EricPFierce

@CarlyHFierce: GSK officially under investigation by Britain's Serious Fraud Office. Release | Follow @CarlyHFierce

> Pfizer ($PFE) rolled out Nexium24HR, its over-the-counter version, under a license deal with the prescription version's maker, AstraZeneca ($AZN). Whether the OTC med will face generic Nexium competition isn't clear, thanks to the Indian drugmaker Ranbaxy Laboratories. Report (reg. req.)

> Celgene ($CELG) appears to have come out ahead in an initial hearing over its Revlimid patent fight with the would-be copycat drugmaker, Natco Pharma. Report

> Adcock Ingram, which spurned a takeover attempt by CFR Pharmaceuticals, posted a first-half loss on deal-cost writedowns; its new CEO plans a wholesale restructuring of the business. Report | Report

> India's Aurobindo Pharma has made its founder, P.V. Ramaprasad, a billionaire, as its shares have more than tripled over the past year. Report

> Actavis ($ACT) confirmed that AstraZeneca ($AZN) sued for patent infringement after the generics maker filed for FDA approval of its knockoff version of AZ's diabetes treatment Onglyza. Report

Medical Device News

@FierceMedDev: Volcano grabs ArtheroMed for up to $130M. News | Follow @FierceMedDev

@VarunSaxena2: RT from FierceMedicalDevices: FDA says recalled pediatric nasal prongs potentially deadly. Story | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: $PFE, $FRX and $LLY dominate top 10 ranking of psych meds. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Biosensors picks a new CEO as revenues slide. Story

> Spectranetics offers up $230M for cardio balloon maker AngioScore. More

> China gives its official thumbs up to Sorin-MicroPort partnership. Report

Biotech News

@FierceBiotech: Turn on, tune in, tweet out for upcoming chat on CAR-T with @JohnCFierce & @PennMedicine's David Porter. #FierceASCO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fast biotech -- Upstart Spark grabs a $73M round to back rapid expansion, PhIII study - gene therapy. News | Follow @JohnCFierce

@DamianFierce: Per @Real_MNA, $SYK not bidding on $SNN but reserves right to do so within 6 mths. Palpable excitement for more UK takeover confusion. | Follow @DamianFierce

@EmilyMFierce: Pace of new MERS infections in Saudi Arabia slows to four a day. More from Reuters | Follow @EmilyMFierce

> Bayer taps Dutch antibody specialist for biologics discovery. More

> Slumping Array aligns with Biogen on early autoimmune R&D. Article

> Valeant dials up its Allergan bid and throws in some R&D promises. Story

> Troubled Trimel touts effect of its female sexual disorder drug Tefina. Report

Drug Delivery News

> PolyTherics picks up Canadian delivery tech for targeted cancer treatment. Article

> Stentys releases data, says CE mark for sirolimus-eluting stent likely. More

> 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story

> Mannkind: Approval of inhaled insulin drug around the corner. Report

> Swiss team develops imaging technique to aid drug delivery in constricted blood vessels. Item

Diagnostics News

> FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug. News

> Roche, undaunted by reimbursement cutbacks, sees no need for Dx price reductions. Report

> In a first, Immucor wins FDA approval for a blood transfusion molecular Dx test. More

> iRhythm has CE mark in sight for arrhythmia Dx patch. Article

> Chinese scientists create viable paper Dx for hepatitis C virus. Story

Pharma Marketing News

> Sanofi, Lilly hook up to switch impotence remedy Cialis to OTC. Story

> J&J launches 'quantified self' app to game patients into better behavior. Article

> Takeda's colitis med Entyvio wins European OK on heels of FDA's approval. Item

> Sanofi's new MS med scores a spot on U.K.'s NHS formulary. More

> Pfizer, Forest and Lilly dominate top 10 ranking of psych meds. Story

> Got a problem, doc? In Eli Lilly's brave new sales world, that's a plus. Article

And Finally... Meditation could be the treatment for bad investment decisions. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.